Tiziana Life Sciences Ltd. Share Price

Tiziana Life Sciences Ltd. Share Price

NASDAQ: TLSA
$0.93
-$0.02 (-2.49%) Last updated on 29 Oct, 2026 | 20:32 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Tiziana Life Sciences Ltd. Stock Performance

Open
$0.95
Prev. Close
$0.95
Circuit Range
N/A
Day Range
$0.93 - $0.95
Year Range
$0.76 - $1.94
Volume
1,114
Average Traded
$0.94

Tiziana Life Sciences Ltd. Share Price Today

As of 29 October 2026, Tiziana Life Sciences Ltd.'s share price is $0.93. The stock opened at $0.95, compared to its previous close of $0.95. During today's trading session, Tiziana Life Sciences Ltd.'s share price traded between $0.93 and $0.95, with an average price of $0.94. Over the past 52 weeks, the stock has recorded a high of $1.94 and a low of $0.76. In terms of performance, Tiziana Life Sciences Ltd.'s share price has declined by 27.91% over the last six months and is down 51.25% on a year-on-year basis.

Tiziana Life Sciences Ltd. Share Price Chart

Line chart of the Tiziana Life Sciences Ltd. price trend over the selected period. The price fell overall, ranging from 0.93 to 0.95, ending at 0.93.
$0.93$0.95
L
Show Current Price
H

Tiziana Life Sciences Ltd. Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
N/A
EPS (TTM)
N/A
Revenue (TTM)
$0.00
Return On Equity (TTM)
N/A
Profit Margin
N/A
Debt to Equity
N/A
Quarterly Earnings Growth YoY
N/A

Tiziana Life Sciences Ltd. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$15.40-$17.69-$11.86-$18.43
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-14.87%32.96%-55.40%

About Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Tiziana Life Sciences Ltd. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.10
$0.93
-16.58%
Sep 2026
$0.96
$1.11
+2.78%
Aug 2026
$1.06
$1.08
+4.85%
Jul 2026
$1.23
$1.03
-18.90%
Jun 2026
$1.41
$1.27
-9.93%
May 2026
$1.31
$1.41
+9.73%
Apr 2026
$1.28
$1.28
+8.44%
Mar 2026
$1.41
$1.19
-18.28%
Feb 2026
$1.49
$1.45
-3.33%
Jan 2026
$1.53
$1.50
+0.67%
Dec 2025
$1.79
$1.49
-15.82%
Nov 2025
$1.85
$1.77
-6.84%

TLSA Share Price FAQs